Lipocine Inc.
Price Action
Technical Summary
CONSOLIDATINGLipocine Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 5), showing significant lag compared to the market leaders. Earnings contraction of 206% provides fundamental context to the price action. Investors should exercise caution due to high volatility (112% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.37 | +2.75% | ABOVE |
| 50 SMA | $5.30 | -54.17% | BELOW |
| 100 SMA | $6.60 | -63.19% | BELOW |
| 150 SMA | $5.41 | -55.06% | BELOW |
| 200 SMA | $4.81 | -49.44% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is LPCN in an uptrend right now?
LPCN has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is LPCN overbought or oversold?
LPCN's RSI (14) is 32. The stock is in neutral territory, neither overbought nor oversold.
Is LPCN outperforming the market?
LPCN has a Relative Strength (RS) Rating of 5 out of 99. LPCN is currently lagging the broader market.
Where is LPCN in its 52-week range?
LPCN is trading at $2.43, which is 20% of its 52-week high ($12.37) and 6% above its 52-week low ($1.81).
How volatile is LPCN?
LPCN has a Beta of 0.86 and 52-week volatility of 112%. It's less volatile than the S&P 500 - generally more stable.